Regulation of programmed cell death by the p53 pathway.

[1]  Horst Kessler,et al.  WT p53, but Not Tumor-derived Mutants, Bind to Bcl2 via the DNA Binding Domain and Induce Mitochondrial Permeabilization* , 2006, Journal of Biological Chemistry.

[2]  S. Ichwan,et al.  Defect in serine 46 phosphorylation of p53 contributes to acquisition of p53 resistance in oral squamous cell carcinoma cells , 2006, Oncogene.

[3]  Rebecca A. Ihrie,et al.  Adult mice lacking the p53/p63 target gene Perp are not predisposed to spontaneous tumorigenesis but display features of ectodermal dysplasia syndromes , 2006, Cell Death and Differentiation.

[4]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Ellisen,et al.  p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. , 2006, Cancer cell.

[6]  A. Look,et al.  Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma , 2005, Cell.

[7]  K. Schulze-Osthoff,et al.  Irradiation-induced Translocation of p53 to Mitochondria in the Absence of Apoptosis* , 2005, Journal of Biological Chemistry.

[8]  F. Shanahan,et al.  Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo. , 2005, Cancer research.

[9]  F. Khuri,et al.  Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. , 2005, Cancer research.

[10]  T. Kuwana,et al.  PUMA Couples the Nuclear and Cytoplasmic Proapoptotic Function of p53 , 2005, Science.

[11]  S. Korsmeyer,et al.  A Role for Proapoptotic BID in the DNA-Damage Response , 2005, Cell.

[12]  Y. Lerenthal,et al.  Proapoptotic BID Is an ATM Effector in the DNA-Damage Response , 2005, Cell.

[13]  S. Gibson,et al.  Transcription Factor NF-κB Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1 , 2005, Molecular and Cellular Biology.

[14]  K. Wiman,et al.  PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis , 2005, Oncogene.

[15]  K. Packman,et al.  Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells , 2005, Cell Death and Differentiation.

[16]  D. Leaman,et al.  Involvement of Noxa in Cellular Apoptotic Responses to Interferon, Double-stranded RNA, and Virus Infection* , 2005, Journal of Biological Chemistry.

[17]  Rebecca A. Ihrie,et al.  Perp Is a p63-Regulated Gene Essential for Epithelial Integrity , 2005, Cell.

[18]  S. L. Davis,et al.  Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness. , 2005, Cancer research.

[19]  S. Lowe,et al.  DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis , 2005, Molecular and Cellular Biology.

[20]  Jing Wu,et al.  Augmentation of antitumor effects of p53 Gene therapy by combination with HDAC inhibitor , 2005, Cancer biology & therapy.

[21]  C. Richon,et al.  p53 Potentiation of Tumor Cell Susceptibility to CTL Involves Fas and Mitochondrial Pathways1 , 2005, The Journal of Immunology.

[22]  Philippe Juin,et al.  The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. , 2004, Molecular cell.

[23]  T. Burns,et al.  Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. , 2004, Cancer cell.

[24]  H. Arakawa,et al.  Netrin-1 and its receptors in tumorigenesis , 2004, Nature Reviews Cancer.

[25]  Yigong Shi,et al.  Molecular mechanisms of caspase regulation during apoptosis , 2004, Nature Reviews Molecular Cell Biology.

[26]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[27]  W. El-Deiry,et al.  Inducible Silencing of KILLER/DR5 In vivo Promotes Bioluminescent Colon Tumor Xenograft Growth and Confers Resistance to Chemotherapeutic Agent 5-Fluorouracil , 2004, Cancer Research.

[28]  W. El-Deiry,et al.  Targeting p53 by PTD-mediated transduction. , 2004, Trends in biotechnology.

[29]  F. Khuri,et al.  p53 Upregulates Death Receptor 4 Expression through an Intronic p53 Binding Site , 2004, Cancer Research.

[30]  U. McDermott,et al.  The Roles of Thymidylate Synthase and p53 in Regulating Fas-Mediated Apoptosis in Response to Antimetabolites , 2004, Clinical Cancer Research.

[31]  Hua Lu,et al.  MDM2 Mediates p300/CREB-binding Protein-associated Factor Ubiquitination and Degradation* , 2004, Journal of Biological Chemistry.

[32]  K. Debatin,et al.  Mutation analysis of the apoptotic “death‐receptors” and the adaptors TRADD and FADD/MORT‐1 in osteosarcoma tumor samples and osteosarcoma cell lines , 2004, International journal of cancer.

[33]  Patrick Dumont,et al.  Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex , 2004, Nature Cell Biology.

[34]  D. Bredesen,et al.  Apoptosis and dependence receptors: a molecular basis for cellular addiction. , 2004, Physiological reviews.

[35]  J. Redondo,et al.  Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Decoy Receptor TRAIL-R3 Is Up-regulated by p53 in Breast Tumor Cells through a Mechanism Involving an Intronic p53-binding Site* , 2004, Journal of Biological Chemistry.

[36]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[37]  E. Snyder,et al.  Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide , 2004, PLoS biology.

[38]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[39]  T. Takayama,et al.  Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. , 2003, Cancer research.

[40]  W. El-Deiry,et al.  Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[42]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[43]  W. El-Deiry.  The role of p53 in chemosensitivity and radiosensitivity , 2003, Oncogene.

[44]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[45]  S. Akira,et al.  Integral role of Noxa in p53-mediated apoptotic response. , 2003, Genes & development.

[46]  Gang Li,et al.  Tissue-specific regulation of Apaf-1 expression by p53. , 2003, Oncology reports.

[47]  T. Burns,et al.  Silencing of the Novel p53 Target Gene Snk/Plk2 Leads to Mitotic Catastrophe in Paclitaxel (Taxol)-Exposed Cells , 2003, Molecular and Cellular Biology.

[48]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[49]  W. El-Deiry,et al.  Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding , 2003, Molecular and Cellular Biology.

[50]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[51]  Yusuke Nakamura,et al.  p53RDL1 regulates p53-dependent apoptosis , 2003, Nature Cell Biology.

[52]  YOUHAI H. Chen,et al.  Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice , 2003, Nature Immunology.

[53]  K. Kinzler,et al.  PUMA mediates the apoptotic response to p53 in colorectal cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  S. Lowe,et al.  Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.

[55]  M. Oren,et al.  The p53-Mdm2 module and the ubiquitin system. , 2003, Seminars in cancer biology.

[56]  W. El-Deiry,et al.  Tissue-specific induction of p53 targets in vivo. , 2002, Cancer research.

[57]  Joanna K. Sax,et al.  BID regulation by p53 contributes to chemosensitivity , 2002, Nature Cell Biology.

[58]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[59]  W. El-Deiry,et al.  Apoptotic threshold is lowered by p53 transactivation of caspase-6 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Peter Schow,et al.  Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax , 2002, Nature Medicine.

[61]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[62]  Jiandong Chen,et al.  Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53* , 2002, The Journal of Biological Chemistry.

[63]  W. El-Deiry,et al.  The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis , 2002, Cancer biology & therapy.

[64]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[65]  S. Xiao,et al.  Sp1 is the major fasl gene activator in abnormal CD4–CD8–B220+ T cells of lpr and gld mice , 2001, European journal of immunology.

[66]  Jiawei Han,et al.  Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[67]  T. Burns,et al.  Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo , 2001, Oncogene.

[68]  Y. Gazitt,et al.  Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. , 2001, Experimental hematology.

[69]  Y Taya,et al.  p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. , 2001, Molecular cell.

[70]  H. S. Kim,et al.  Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. , 2001, Cancer research.

[71]  K. Helin,et al.  Apaf-1 is a transcriptional target for E2F and p53 , 2001, Nature Cell Biology.

[72]  T. Rebbeck,et al.  Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[74]  Sanjeev Gupta,et al.  Direct Transcriptional Activation of Human Caspase-1 by Tumor Suppressor p53* , 2001, The Journal of Biological Chemistry.

[75]  Ettore Appella,et al.  p300/CBP‐mediated p53 acetylation is commonly induced by p53‐activating agents and inhibited by MDM2 , 2001, The EMBO journal.

[76]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[77]  K. Kinzler,et al.  PUMA induces the rapid apoptosis of colorectal cancer cells. , 2001, Molecular cell.

[78]  Yoichi Taya,et al.  Regulation of p53 by Hypoxia: Dissociation of Transcriptional Repression and Apoptosis from p53-Dependent Transactivation , 2001, Molecular and Cellular Biology.

[79]  M. Shin,et al.  Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma , 2001, Oncogene.

[80]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[81]  Caroline A Heckman,et al.  Negative regulation of bcl-2 expression by p53 in hematopoietic cells , 2001, Oncogene.

[82]  S. Korsmeyer,et al.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. , 2000, Molecular cell.

[83]  S. Korsmeyer,et al.  Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. , 2000, Science.

[84]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[85]  R. Hay,et al.  Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation , 2000, Molecular and Cellular Biology.

[86]  Yusuke Nakamura,et al.  p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53 , 2000, Cell.

[87]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[88]  N. Spinner,et al.  Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. , 2000, International journal of oncology.

[89]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[90]  S. Lowe,et al.  PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. , 2000, Genes & development.

[91]  J. Roth,et al.  Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  E. May,et al.  Human and Mouse Fas (APO-1/CD95) Death Receptor Genes Each Contain a p53-responsive Element That Is Activated by p53 Mutants Unable to Induce Apoptosis* , 2000, The Journal of Biological Chemistry.

[93]  A. Fornace,et al.  The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[94]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[95]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[96]  S. Nagata,et al.  Fas ligand-induced apoptosis. , 1999, Annual review of genetics.

[97]  A. Levine,et al.  Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. , 1999, Genes & development.

[98]  H. Friess,et al.  The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract , 1999, Oncogene.

[99]  M. Weller,et al.  p53 Enhances BAK and CD95 Expression in Human Malignant Glioma Cells but Does Not Enhance CD95L-Induced Apoptosis , 1999, Cellular Physiology and Biochemistry.

[100]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[101]  L. Owen-Schaub,et al.  Activation-Dependent Transcriptional Regulation of the Human fas Promoter Requires NF-κB p50-p65 Recruitment , 1999, Molecular and Cellular Biology.

[102]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[103]  J P Luzio,et al.  Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. , 1998, Science.

[104]  J. Jen,et al.  Rare loss-of-function mutation of a death receptor gene in head and neck cancer. , 1998, Cancer research.

[105]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[106]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[107]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[108]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[109]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[110]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[111]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[112]  K. A. McKenna,et al.  p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta. , 1997, Cancer research.

[113]  Matthias Mann,et al.  FLICE is activated by association with the CD95 death‐inducing signaling complex (DISC) , 1997, The EMBO journal.

[114]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[115]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[116]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[117]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[118]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[119]  T. Jacks,et al.  Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells. , 1996, Oncogene.

[120]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[121]  D. Lane,et al.  Small peptides activate the latent sequence-specific DNA binding function of p53 , 1995, Cell.

[122]  J. Roth,et al.  Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression , 1995, Molecular and cellular biology.

[123]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[124]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.